Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma
A. Acuña, I. Rojas, D. De Pascuali, M. Saad, L. Barroeta, M. Carrabs (Caracas, Vargas, Maracaibo, Venezuela)
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Session: Managing asthma and allergic disease in children
Session type: Thematic Poster Session
Number: 2645
Disease area: Airway diseases, Paediatric lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Acuña, I. Rojas, D. De Pascuali, M. Saad, L. Barroeta, M. Carrabs (Caracas, Vargas, Maracaibo, Venezuela). Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma. Eur Respir J 2010; 36: Suppl. 54, 2645
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Randomized clinical trial (RCT) comparing formoterol vs. salbutamol plus ipratropium bromide in the treatment of acute asthma exacerbation (AE) at emergency room (ER) Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005
Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
A randomised, 4-way crossover study to examine the lung pharmacodynamic effects of single inhaled doses of tiotropium (18 μg), salmeterol (50 μg), tiotropium (18 μg) and salmeterol (50 μg) and placebo using whole body plethysmography in healthy subjects Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
The effect of high dose N-acetylcysteine (1200mg daily) on airway function and airway trapping in COPD patients — A double blinded randomized placebo controlled trial Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Source: Eur Respir J 2002; 20: 1138-1146 Year: 2002
A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001
A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009
Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013
A randomised double-blind, study to determine the efficacy & safety of a once-daily inhaled β2 adrenoreceptor agonist, PF-00610355 in asthmatic patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009
Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017
A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics Source: Eur Respir J 2006; 28: Suppl. 50, 210s Year: 2006
Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009